In this interview ahead of the 2024 American Society of Clinical Oncology annual meeting (ASCO), Ravin Ratan, MD, MEd, The University of Texas MD Anderson Cancer Center, discusses study data he is excited to hear more about on the combination of trabectedin and low-dose irinotecan for relapsed/refractory Ewing sarcoma.
/PRNewswire/ PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced encouraging preliminary safety and efficacy results from its Phase 1B study of unesbulin.